Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.48 |
| ▸ | VNN1 | O95497 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131490 | 0.88 | GSK3B (0.48) | CDC7VNN1NAMPTROCK2MAP4K4 | |
| SCHEMBL7737558 | 0.86 | KDR (0.47) | CDC7VNN1ROCK2MAP4K4GSK3B | |
| SCHEMBL5694501 | 0.85 | ROCK2 (0.47) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL7738450 | 0.85 | RET (0.55) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL7732439 | 0.84 | KDR (0.55) | VNN1ROCK2GSK3BCLK4MKNK2 | |
| SCHEMBL7460271 | 0.81 | CDC7 (0.46) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| Hydrochloric Acid SCHEMBL9960799 | 0.78 | CDC7 (0.46) | CDC7ROCK2MAP4K4GSK3BCLK4 | |
| SCHEMBL8814921 | 0.77 | CDC7 (0.58) | CDC7ROCK2MAP4K4CLK4MKNK2 | |
| SCHEMBL6680013 | 0.77 | CDC7 (0.40) | CDC7VNN1ROCK2MAP4K4GSK3B | |
| SCHEMBL7739113 | 0.76 | CDC7 (0.43) | CDC7NAMPTROCK2MAP4K4GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | CDC7 3304/4885VNN1 1365/4885NAMPT 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.